Effect Of Seretide On Airway Inflammation And Pulmonary Function In Patients With Copd

Objective:Understand salmeterol with fluticasone (Seretide) for patients with chronic obstructive pulmonary disease with airway inflammation, with pulmonary ventilation function.Method:On September 2008-2010, February outpatient or hospitalization after lung function of the 35 patients were diagnosed patients with COPD, stationary Seretide stack (including rules inhaled salmeterol 50ug, with fluticasone 500ug a, the BID) 3 months. In January, the treatment before treatment, march record the patient lung ventilation function results, st. George's life quality assessment (SGRQ), sputum and induced sputum inflammatory cells classification and count (neutrophils, lymphocytes, eosinophils, macrophages). Using ria analysis and ELISA method for three months before treatment, treatment after January, induced sputum and march sputum inflammation(IL-8, IL-6, MPO, ECP, EPO, MMP-9, TIMP-1)content analysis, and statistical analysis.Results:1.35 cases, severe stable patients with COPD treatment after January, march SGRQ score, FEV1% of expected value and FEV1/FVC%(32.57±4.38 points, 47.05±8.13,56.37±7.37%; 21.6±5.00points,51.69±8.41%,57.79±6.28%) before treatment (42.97±47points,43.96±7.94%,52.88±7.45%)obviously improved(P< 0.01);2.35 cases, severe stable patients with COPD treatment after January and march induced sputum inflammatory cells, lymphocytes, neutrophils eosinophils, macrophages percentage (68.08±5.48%,10.82±1.15%,1.42±0.77%,4.34±1.62%; 63.40±6.79%,8.77±1.59%,1.45±0.56%,3.71±1.17%) was (72.37±6.90%,12.00±1.08%,2.28±0.95%,4.37±1.08%) declined obviously (P<0.01);3.35 cases, severe stable patients with COPD treatment after January and march induced sputum inflammation (IL-6, IL-8, MPO, ECP, EPO, MMP-9, TIMP-1) level (326.95±85.13pg/ml,1.40±0.48ng/ml,2.94±0.77ng/ml,5.31±1.04ng/ml, 2.94±0.77ng/ml,1.79±0.21ng/ml,1.23±0.17ng/ml和283.84±75.1pg/ml,0.98±0.35ng/ml,2.39±0.70ng/ml±5.31±1.04ng/ml,2.39±0.70ng/ml,1.53±0.34ng/ml,1.08±0.14ng/ml) before treatment (417.56±94.54pg/ml,2.28±0.94ng/ml,3.66±1.08ng/ml,6.22±1.49ng/ml,3.66±1.08ng/ml,2.21±0.82ng/ml,1.39±0.26ng/ml) decreased obviously (P<0.01);4.35 cases, severe stable patients with COPD before and after treatment with st. George's rating of expected value and FEV1% FEV1/FVC% is negative correlation (P＜0.05). Induced sputum neutrophils are expected to FEV1% accounts and FEV1/FVC% negatively correlated (P＜0.05). Inflammation (IL-8,IL-6,MPO,ECP,EPO,MMP-9, TIMP-1) before and after the treatment level and FEV1% of expected and FEV1/FVC% negatively correlated (P＜0.05).Conclusion:(1) Seretide stack reduce the moderate stable patients with COPD induced sputum of inflammatory cells and inflammationMedium level. (2) Seretide can improve patients with COPD lung ventilation function, to alleviate the symptoms, and improve the quality of life. (3) Patients with COPD phlegmy in inflammatory cells are mainly neutrophils, and pulmonary ventilation function was negatively correlated, can reflect the severity of COPD. (4) Patients with COPD phlegmy in inflammation levels and lung ventilation function negativel。...